Skip to main content

Trangenomic s Q4 Sales Decline 21 Percent As Net Loss Nearly Doubles

NEW YORK, March 17 (GenomeWeb News) - Transgenomic yesterday reported a 21.3-percent decrease in net sales and a greater net loss for the fourth quarter.


Sales for the three months ended Dec. 31, 2005, declined to $5.3 million from $6.8 million in the year-ago period.


The company's net loss for the fourth quarter almost doubled to $11.2 million, compared with $6.9 million in Q4 2005.


Transgenomic did not break out its R&D expenses.


As of Dec. 31, Transgenomic had $6.7 million in cash and cash equivalents.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.